Dornase Alfa in the Treatment of Cystic Fibrosis in Europe: A Report from the Epidemiologic Registry of Cystic Fibrosis

Pediatric Pulmonology

Volumn 36, Issue 5, 2003, Pages 427-432

  Hodson, M E ^a,h   McKenzie, S ^b   Harms, H K ^c   Koch, C ^d   Mastella, G ^e   Navarro, J ^f   Strandvik, B ^g  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d Rigshospitalet   (Denmark)

^e Cystic Fibrosis Center   (Italy)

^f HÔPITAL ROBERT DEBRÉ   (France)

^g QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^h ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cystic fibrosis; Dornase alfa; Lung function; Registry data

Indexed keywords

DORNASE ALFA;

ADOLESCENT; ARTICLE; CHILD; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DATA ANALYSIS; DATA BASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EPIDEMIOLOGIC REGISTRY OF CYSTIC FIBROSIS; EUROPE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LONG TERM CARE; LUNG FUNCTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGISTER;

ADOLESCENT; AGE DISTRIBUTION; CHILD; CONFIDENCE INTERVALS; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; DRUG EVALUATION; EUROPE; FEMALE; HUMANS; MALE; REFERENCE VALUES; REGISTRIES; RESPIRATORY FUNCTION TESTS; SEX DISTRIBUTION; TREATMENT OUTCOME;

EID: 0142062982     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.10348     Document Type: Article

References (21)

1. Dodge JA, Morrison S, Lewis PA, et al. Incidence, population and survival of cystic fibrosis in the UK 1968-95. Arch Dis Child 1997;77:493-496.
2. Penketh AR, Wise A, Mearns MB, et al. Cystic fibrosis in adolescents and adults. Thorax 1987;42:526-532.
3. Lethern MI, James SL, Marriott C, Burke JE. The origin of DNA associated with mucus glucoproteins in cystic fibrosis sputum. Eur Respir J 1990;3:19-23.
4. Ranasinha C, Assoufi B, Shak S, et al. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet 1993; 342:199-202.
5. Ramsey BW, Astley SJ, Aitken ML, et al. Efficacy and safety of short-term administration of aerosolised recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993;148:145-151.
6. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolised recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function inpatients with cystic fibrosis. N Engl J Med 1994;331:637-642.
7. Shah PL, Scott SF, Fuchs HJ, et al. Medium-term treatment with recombinant human DNase 1. Thorax 1995;50: 333-338.
8. Quan JM, Tiddens HAWM, Sy JP, et al. A two-year randomised placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001;139:813-820.
9. Shah PL, Bush A, Canny GJ, et al. Recombinant human DNase 1 (rhDNase) in cystic fibrosis patients with severe pulmonary disease: a short-term double-blind study followed by six months' open-label treatment. Eur Respir J 1995;8:954-958.
10. McCoy K, Hamilton S, Johnson C, for the Dornase Alfa Study Group. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Chest 1996; 110:889-895.
11. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow volume curve with growth and aging. Am Rev Respir Dis 1983;127:725-734.
12. Hibbert ME, Lannigan A, Landau LI, Phelan PD. Lung function values from a longitudinal study of healthy children and adolescents. Pediatr Pulmonol 1989;7:101-109.
13. Hodson ME, Koch C, Harries HK, et al. The European Epidemiologic Registry of Cystic Fibrosis (ERCF). Does domase alfa make any difference? In: Proceedings of the 22nd European CF Conference; 1998 June 13-19; Berlin, Germany. Berlin: European CF Conference; 1998. p 66.
14. Armstrong DS, Grimwood K, Carzino R, et al. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. Br Med J [Clin Res] 1995;310:1571-1572.
15. Khan TZ, Wagener JS, Bost T, et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995;151:1075-1082.
16. Cantin A. Cystic fibrosis lung inflammation: early, sustained and severe. Am J Respir Crit Care Med 1995;151:939-941.
17. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995;332:848-854.
18. Johnson CA, Butler SM, Konstan MW, Breen TJ, Morgan WJ. Estimating effectiveness in an observational study: a case study of dornase alfa in cystic fibrosis. J Pediatr 1999;134:734-739.
19. Mastella G, Rainisio M, Harms HK, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Eur Respir J 2000;16:464-471.
20. Koch C, Cuppens H, Rainisio M, et al. European Epidemiologic Registry of Cystic Fibrosis (ERCF) comparison of major disease manifestations between patients with different classes of mutations. Pediatr Pulmonol 2000;31:1-12.
21. Burrows A, Bunting JP, Masel PJ, Bell SC. Nebulised domase alpha: adherence in adults with cystic fibrosis. J Cystic Fibrosis 2002;1:255-259.